Introduction
The Tbx family of transcription factors perform a variety of functions critical to early embryonic development (Smith, 1999) . The prototypical Tbx protein brachyury is required for posterior, axial and paraxial mesoderm formation as well as formation of the notochord (Smith, 1999) . Whereas homozygous mutations in Brachyury cause early embryonic lethality, heterozygous Brachyury mutations are responsible for the classical mouse mutant tailess (Herrmann et al., 1990) . Although mutations in Brachyury have not been linked to any human disease or birth defects, mutations in a number of other Tbx genes have. These include Tbx1 (DiGeorge syndrome, see Schinke and Izumo (2001) for review), Tbx3 (ulnar-mammary syndrome, Bamshad et al., 1997) , Tbx5 (Holt-Oram syndrome, Basson et al., 1997; Li et al., 1997) and Tbx22 (X-linked cleft palate and ankyloglossia, Braybrook et al., 2001) . Consistent with known functions of Brachyury, a common theme amongst the human disease syndromes caused by mutations in Tbx family genes is the disruption of regional epithelial/mesodermal interactions and associated defects in mesoderm induction and dierentiation events.
Ulnar-mammary syndrome (UMS), caused by heterozygous mutations in Tbx3 (Bamshad et al., 1997 , is an autosomal dominant disorder characterized by de®ciencies and duplications of posterior elements of the forelimb, by mammary hypoplasia and apocrine gland de®ciency/dysfunction and by tooth, hair and sex organ defects. Tbx3 is related to Brachyury and other Tbx family members by their shared DNA-binding motif known as the T-domain. Some mutations in Tbx3 that cause UMS disrupt the T-domain and are thought to function as null alleles (Bamshad et al., 1997) , but others occur downstream from the Tdomain and may aect the transcriptional repression activity or other functions of Tbx3 He et al., 1999; Carlson et al., 2001) . The range and nature of defects associated with UMS, together with sites of Tbx3 expression Gibson-Brown et al., 1998) are consistent with a key role of Tbx3 as a mediator of regional mesoderm induction and dierentiation. However, very little is known concerning the underlying molecular mechanisms responsible for such activity.
Whereas the relationship between most Tbx family members is limited to the conserved T-domain, Tbx2 and Tbx3 show much more extensive sequence relationship. Indeed the Tbx2/Tbx3 gene pair and the more distantly related Tbx4/Tbx5 gene pair is thought to have evolved from an ancestral gene through a twostep process involving an initial tandem duplication event followed by a parallel duplication event . Beyond the sequence similarities, it is now known that Tbx2 and Tbx3 both behave as transcriptional repressors and contain a conserved repression domain in their C-terminus (He et al., 1999; Carlson et al., 2001) . Tbx3 and Tbx2 also share similar, but not identical expression patterns during embryonic development Gibson-Brown et al., 1998) . However, mutations in Tbx2 have not been found associated with UMS or any other disease syndrome and the apparent haploinsuciency basis for UMS supports the notion that Tbx2 and Tbx3 do not have absolutely redundant functions during embryonic development. Nonetheless, the close sequence relationship between Tbx3 and Tbx2 suggests that these proteins may share redundant biological activities.
Recent cell culture assay systems demonstrate that Tbx2 has functions that impinge on the replicative lifespan of mouse and human ®broblasts (Jacobs et al., 2000) . Tbx2 was found capable of bypassing the premature senescence phenotype of mouse embryo ®broblasts lacking the polycomb group protein Bmi1 (Jacobs et al., 2000) . Further, Tbx2 and, more recently, Tbx3, was found capable of immortalizing primary mouse embryo ®broblasts (Jacobs et al., 2000; Carlson et al., 2001; Brummelkamp et al., 2002) . The underlying mechanism for the ability of Tbx2 and Tbx3 to prevent senescence and immortalize cells appears to be through transcriptional repression of the Cdkn2a (p19ARF) gene (Jacobs et al., 2000; Brummelkamp et al., 2002) . Since cells lacking p19ARF fail to senesce in culture and can be propagated inde®nitely (Kamijo et al., 1997) , downregulation of p19ARF by Tbx2 and Tbx3 provides a molecular explanation for its ability to immortalize cells. p19ARF regulates the abundance of p53 tumor suppressor protein through its physical interaction with Mdm2 oncoprotein, a ubiquitin ligase that mediates the degradation of p53 (Sherr and Weber, 2000; Sharpless and DePinho, 1999) . Binding of p19ARF to Mdm2 blocks Mdm2 nucleo-cytoplasmic shuttling and sequesters it to the nucleolus, thus preventing its targeting of p53 for destruction (Tao and Levine, 1999) . It is therefore predicted, but has not yet been demonstrated, that downregulation of p19ARF and immortalization by Tbx2 and Tbx3 should correlate with decreased levels of p53 and suppression of its cell cycle arrest/senescence functions.
In addition to its functions in regulating cellular lifespan, the p19ARF/Mdm2/p53 pathway plays an important role in regulating apoptosis (Sherr and Weber, 2000; Sharpless and DePinho, 1999) . One way that the apoptotic function of the p19ARF/MDM2/ p53 pathway is activated, is in response to excessive proliferation stimuli, such as that caused by oncogene activation/overexpression. For example, oncogenes such as Myc and Ras induce p19ARF expression and consequently allow stabilization and accumulation of p53 (Serrano et al., 1997; Zindy et al., 1998; Palmero et al., 1998) . Such increased p53 levels promote apoptosis and/or cell cycle arrest and this function is hypothesized to serve as a default mechanism to promote the destruction, or interfere with the progression of cancer prone cells (Evan and Vousden, 2001) . Furthermore, mutations that disrupt p53-mediated apoptosis appear central to cancer development. Thus the ability of Tbx2 to downregulate p19ARF, together with the ®nding that it is ampli®ed in a subset of mammary carcinomas, has raised the possibility that it may function as an oncogene (Jacobs et al., 2000) . In this study, we demonstrate that Tbx3 downregulates p19ARF and p53 levels in cells, can suppress apoptosis and facilitate cell transformation by Myc and Ras oncogenes and interfere with myogenic dierentiation. Our results suggest that events leading to excessive expression levels of Tbx3 may contribute to tumorigenesis in vivo, and that defective regulation of p53 caused by mutations in Tbx3 may be at least partly responsible for ulnar-mammary syndrome.
Results

Tbx3 cooperates with Myc and Ras to transform cells
We previously showed that ectopic expression of Tbx3 was capable of immortalizing primary MEFs (Carlson et al., 2001) . Since cell immortalizing events, such as mutation or loss of p19ARF or p53 are required for oncogenic transformation or progression caused by oncoproteins such as Myc and oncogenic H-Ras (Serrano et al., 1997; Zindy et al., 1998; Palmero et al., 1998) (Figure 1a,b) . Further, coexpression of Tbx3 with Myc and H-Ras V12 resulted in the production of far more foci than observed with Myc and H-Ras V12 alone (Figure 1a,b) . These results suggest that functions associated with the ability of Tbx3 to immortalize cells (Carlson et al., 2001) , allows Tbx3 to facilitate cell transformation by Myc and HRas V12 oncoproteins. In addition to focus-formation, cells infected with Tbx3 and Myc or Tbx3 and H-Ras V12 were tested for the ability to form colonies in soft agar. Transfected MEFs were allowed to grow for 2 weeks, at which time transformed foci became visible in Tbx3 plus Myc, Tbx3 plus H-Ras V12 and H-Ras V12 plus Myc populations. Cells were pooled from individual transfectant populations, plated in soft agar and the number of colonies formed were counted 3 weeks later. Tbx3 expression was found to have little or no ability to promote soft agar colony formation in the presence of H-Ras V12 , Myc or H-Ras V12 plus Myc (data not shown).
Tbx3 downregulates p19ARF and p53 and protects against Myc-induced apoptosis
Thus the ability of Tbx3 to immortalize MEFs and facilitate cell transformation by ectopic expression of Myc and H-Ras V12 , suggested that Tbx3 might exert its activity by interfering with p53 pathway functions. Further, the closely related Tbx2 protein was previously demonstrated to downregulate the p19ARF gene (Jacobs et al., 2000) . We examined the expression of p19ARF, Mdm2, p53 and levels of the p53 target gene product p21, in cells infected with Tbx3 and in cells sequentially transfected with Tbx3 and c-Myc or H-Ras (Figure 2a ). Coinfection eciencies using this protocol were typically in the range of 25 ± 50%, based on the infection eciency of a control green-¯uorescent protein-expressing virus (not shown). Levels of p19ARF were found to be downregulated by Tbx3 alone and the elevated p19ARF levels caused by Myc or H-Ras overexpression were suppressed in the presence of Tbx3 (Figure 2a ). Consistent with downregulation of p19ARF levels, the elevated levels of p53 and p21 in cells overexpressing Myc and Ras were downregulated in the presence of Tbx3 (Figure 2a ). In contrast to p19ARF, levels of p16 (Cdkn1a) were not aected by Tbx3, but were upregulated by H-Ras as previously reported (Serrano et al., 1997) . Examination of total pRb levels demonstrated the presence of a slower mobility species that appeared most abundant in Tbx3-expressing cells. The presence of a slower mobility form(s) of pRb is consistent with hyper-phosphorylation and inactivation of Rb. Using antibodies that speci®cally recognize phosphorylated forms of pRb, a form of pRb speci®cally phosphorylated at Ser 807/810 was detected. Phosphorylation of pRb at 807/811 within the pRb`C-pocket' has been demonstrated to cause release of bound Abl tyrosine kinase Wang, 1993, 1995) . Unlike the 807/811-phosphorylated form of pRb, we were unable to consistently show the presence of other phosphorylated forms, nor were we able to demonstrate increased activity of cyclin-dependent kinase 2, 4 or 6 (data not shown).
Primary cells overexpressing Myc are prone to apoptosis under serum (survival factor) ± limiting condition (Evan and Vousden, 2001 ) and several studies indicate the disruption of p53 pathway functions associated with apoptosis is required, or greatly facilitates Myc-induced oncogenic transformation (Zindy et al., 1998; Eischen et al., 1999; Jacobs et al., 1999; Maestro et al., 1999) . Therefore we next examined the ability of Tbx3 to suppress apoptosis and its aects on the cell cycle. MEFs expressing Tbx3 alone or in combination with Myc or Ras were subjected to serum-limiting conditions (0.2% fetal bovine serum) for 48 h and apoptotic cells identi®ed by FACS analysis of propidium iodide-stained cells. As shown in Figure 2b Since the sequential viral infection protocol used in the above experiments allowed only a fraction of the target cells to be infected, a second approach was used to examine the extent to which Tbx3 could protect cells against Myc-dependent apoptosis. For these experiments, we took advantage of an immortal ®broblast cell line developed by Mateyak et al. (1999) called HO ± Myc, which lacks endogenous cMyc, but expresses ectopic, deregulated c-Myc at levels that are moderately elevated compared to its parental Rat1a cell line. Under normal serum levels (10%) these cells grow similarly to wild-type cells, but when deprived of serum, are highly prone to apoptosis (Mateyak et al., 1999) . We used retroviral infection to introduce Tbx3 and a mutant form of Tbx3 lacking the entire C-terminus downstream from the T-domain (Tbx3-300, Carlson et al., 2001) into HO-Myc cells and examined the apoptotic response following reduction of serum levels to 0.2% (Figure  3a,b) . Retroviral infection eciencies using HO-Myc cells were typically 65 ± 80% (not shown). When infected with either empty vector or Tbx3-300, HOMyc cells showed a strong apoptotic response. In contrast, HO-Myc cells infected with Tbx3 virus showed signi®cant resistance to apoptosis (Figure  3a,b) . However, by 96 h, many of the Tbx3-infected population had succumbed to apoptosis (Figure  3a,b) . In comparison, overexpression of Bcl2 in HO-Myc cells resulted in at least a 2-fold greater Figure 2 Eects of Tbx3 expression on levels of p53 pathway proteins and apoptosis. Primary MEFs at passage 1 were infected with empty virus, Tbx3, Myc, or Ras virus alone. For co-expression of Tbx3 with Myc and with Ras, Tbx3 infected cells were subsequently infected with either empty virus or by Myc or Ras viruses. For the singly expressing Tbx3, Myc and Ras cell populations, a second infection procedure was also performed, but with empty virus. Infected cells were harvested 2 days after the second infection for Western blot analysis (a) or for FACS analysis (b). For Western blots, equal amounts of cell extracts were used to determine the relative levels of the indicated proteins using antibodies listed in Materials and methods. Tbx3 and Tbx3-300 proteins contain Ha-antibody epitopes at their C-termini (Carlson et al., 2001) . For FACS analysis, cells were ®xed in 70% ethanol and stained with propidium iodide. Relative DNA content of individual cells is shown in (b), with the growth phase 1 (G1, diploid DNA content) and growth phase 2/mitosis (G1/M, tetraploid DNA content) populations indicated, along with the percentage of apoptotic cells (exhibiting a sub-GI DNA content). Arrows point to cells infected with Myc and with Tbx3 plus Myc that show a sub-G1 DNA content characteristic of cells undergoing apoptosis. Note the decrease in the population of apoptotic cells that occurs when Tbx3 is coexpressed with Myc. The percentage of apoptosis present in each of the cell populations, based on sub-G1 DNA content is indicated Tbx3 effects on cell growth and differentiation H Carlson et al number of cells protected from apoptosis under identical conditions (not shown). These results suggest that Tbx3 signi®cantly delays the robust apoptotic response of these cells and may protect some HO-Myc cells from death, but does not completely disrupt pathways required for apoptosis.
To examine the eects of Tbx3 on the p53 pathway in HO-Myc cells, levels of p19ARF, p53, Mdm2 and p21 were compared in uninfected cells and in cells infected with Tbx3 and Tbx3-300. Levels of p19ARF were consistently found to be signi®cantly lower in Tbx3 cells, as was p53, and the p53 target gene products Mdm2 and p21 (Figure 3c ). In contrast, Tbx3-300 expression appeared to cause a slight upregulation of p19ARF, p53, Mdm2 and p21 ( Figure  3c ). Thus overexpression of Tbx3 downregulates, but does not shut o expression of p19ARF and p53, and such downregulation is consistent with the observation that Tbx3 partially protects against apoptosis of HOMyc cells.
Suppression of myogenic differentiation by Tbx3
The p53 and pRb pathways play critical roles in the control of myogenic dierentiation (Walsh and Perlman, 1997; Cerone et al., 2000). The ability of Tbx3 Figure 3 Tbx3 suppresses Myc-dependent apoptosis. HO ± Myc cells were infected with viruses expressing the indicated proteins and 2 days later growth medium (10% serum) was replaced with low serum (0.2%) medium. Cells were photographed at the indicated times following lowering the serum (a). The appearance of highly refractile, rounded and picnotic cells are characteristic of apoptosis. To quantitate apoptosis, all cells were collected from empty virus, Tbx3 ± 300 and Tbx3 infected populations at the indicated times, ®xed in 70% ethanol, stained with propidium iodide and DNA content measured by FACS (b). The percentage of apoptotic cells determined by the number of cells showing a sub-G1 (diploid) DNA content is indicated. Represented are the results of two separate experiments performed in duplicate (error bars indicate standard deviations). (c) Reduced expression levels of p53-pathway components caused by Tbx3 in HO ± Myc cells. HO ± Myc cells infected with empty virus, Tbx3 or Tbx3 ± 300 were harvested 2 days following viral infection, lysed and equal amounts of cell extracts used for Western blot analysis of the indicated proteins as described in Materials and methods
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Tbx3 effects on cell growth and differentiation H Carlson et al to regulate p19ARF and p53 levels and to induce phosphorylation and possibly inactivate Rb (Figures  2a and 3c ) led us to test whether ectopic expression of Tbx3 in the myogenic cell line C2C12 could prevent dierentiation. For these experiments, pools of C2C12 cells expressing Tbx3, Tbx3-300 or no Tbx3 protein were generated by stable transfection using G418 selection. These dierent populations were tested for their ability to dierentiate into myotubes when the culture medium was changed from growth medium (15% bovine calf serum) to dierentiation medium (2% horse serum). Whereas vector control cells and Tbx3-300 cells showed an abundance of myotubes following 5 days in dierentiation medium, very few myotubes were observed in the Tbx3 expressing population (Figure 4 ). Consistent with a disrupted dierentiation response, Tbx3 expressing cells failed to upregulate the muscle dierentiation marker myosin light chain (MLC) and the myogenic regulatory factor myogenin ( Figure 5) . Interestingly, the basal levels of both myogenin and myoD were reduced in Tbx3-expressing cells compared to vector control cells, as was MLC, and their expression remained suppressed following exposure to dierentiation medium for 5 days (0 days, Figure 4 ).
It is important to note that Tbx3 expression appeared to be toxic to a sub-population of C2C12 cells and that another sub-population was capable of undergoing dierentiation into myotubes following more extended time in dierentiation medium (not shown). One possibility is that these dierent responses are caused by dierent expression levels of Tbx3 in the pooled populations of transfected cells used in these experiments. Nonetheless, we conclude that Tbx3 expression provides a strong inhibitory signal for myogenic dierentiation.
Discussion
A probable mechanism underlying the ability of Tbx3 to cooperate with Myc and Ras oncogenes to transform cells (Figure 1 ) and to inhibit myogenic dierentiation (Figure 4) is reduction of p53 levels caused by downregulation of p19ARF by Tbx3 (Figures 2a and 3c) . Based on results obtained with Tbx2 (Jacobs et al., 2000) and more recently with Tbx3 (Brummelkamp et al., 2002) , downregulation of p19ARF by these factors is direct. The downregulation of p19ARF by Tbx3 is predicted to decrease cellular levels of p53 by freeing the p19ARF-interacting protein Mdm2, leading to increased Mdm2-mediated turnover of p53 (Sherr and Weber, 2000; Sharpless and DePinho, 1999) . Indeed, we ®nd Figure 4 Tbx3 blocks myogenic dierentiation. C2C12 myogenic cells were transfected with pFB, pFB ± Tbx3 or pFB ± Tbx3 ± 300 and stable transfectants selected by resistance to the G418 resistance conferred by the virus. Pooled populations, growing in 15% fetal bovine serum, were established and examined for their ability to dierentiate when placed in dierentiation medium (2% horse serum). Cells were photographed (406) following incubation in dierentiation medium for the indicated times Figure 5 Northern blot comparing the induction of the muscle dierentiation marker myosin light chain and expression levels of the muscle regulatory factors myogenin and MyoD in control, empty virus infected C2C12 cells and C2C12 cells stably expressing Tbx3. Glyceraldehyde phosphate dehydrogenase (GFAP) served as a loading control Tbx3 effects on cell growth and differentiation H Carlson et al that p53 levels decrease in response to ectopic expression of Tbx3, and that levels of the p53 target gene products Mdm2 (functioning as part of a feedback mechanism regulating p53 abundance) and p21 also decrease (Figures 2a and 3c ). The ability of Tbx3 to downregulate p19ARF, p53 and p53 target gene levels, is consistent with its ability to interfere with myogenic dierentiation, which has been shown to be dependent on p53 activity (Cerone et al., 2000) . Similarly, the ability of Tbx3 to negatively regulate p53 levels is consistent with its capacity to participate in cell transformation. In contrast to Tbx3, both Myc and Ras stimulate increased p19ARF levels and typically make cells prone to apoptosis and cell cycle arrest respectively (Sherr and Weber, 2000; Sharpless and DePinho, 1999) . A likely manifestation of the decreased levels of p53 caused by Tbx3 expression is partial suppression of apoptosis, as we show using primary MEFs overexpressing Myc (Figure 2b ) and the HO ± Myc cell line (Figure 3a,b) . HO ± Myc cells are derivatives of the immortal Rat1a cell line that express deregulated Myc on a myc-null background (Mateyak et al., 1999) and, like many cell types expressing elevated Myc levels, are highly sensitive to apoptosis when serum-deprived. Although Myc-dependent apoptosis was strongly suppressed by Tbx3 in primary MEFs (Figure 2b ), suppression of apoptosis in HO-Myc cells was less impressive (Figure 3a,b) . These results raise the possibility that primary cells may be more responsive to Tbx3 eects on apoptosis than immortal cell lines. Alternatively, the HO ± Myc assay system may provide a more accurate assessment of the protective eects of Tbx3 expression. Nevertheless, we speculate that even a partial disruption of p53-dependent apoptosis caused by downregulation of p19ARF in primary MEFs, is sucient for Tbx3 to tip the balance in favor of growth promotion and cell transformation by Myc. It is important to recognize that Myc-induced apoptosis is manifest much more readily in serum-limiting (survival factor-limiting) conditions and that the cell transformation experiments using Tbx3 in combination with Myc and Ras were performed in normal growth conditions (as these types of experiments are typically performed). Thus, partial disruption of p53-mediated apoptosis by Tbx3, combined with the presence of survival factors above some threshold that buers cells from the apoptotic and cell cycle arrest activities of excessive Myc and Ras levels, likely work together to promote cell transformation by Myc, as well as Ras oncogenes. Indeed, the ability of Tbx3 to cooperate with Myc to transform cells, yet only partially block Myc-dependent apoptosis, suggests that additional activities of Tbx3, or additional activities associated with downregulation of p19ARF, promote cell transformation. The ability of Tbx3 to impinge on p53 pathway function, facilitate cell immortalization and transformation, and inhibit myogenic dierentiation, is consistent with the idea that Tbx3 may participate in tumorigenic progression in vivo. Interestingly, the bHLH protein Twist has properties similar to those described here for Tbx3 and there is evidence that it functions as an oncogenic factor in rhabdomyosarcoma (Maestro et al., 1999) . Jacobs et al. (2000) , who made the original observation that the Tbx2 protein can immortalize MEFs and can repress p19ARF gene transcription, showed that the Tbx2 gene is ampli®ed and overexpressed in some breast cancers. Consistent with the notion that Tbx3 may be capable of promoting neoplastic growth, null and/or inactivating mutations in Tbx3 in humans leads to hypoproliferation of a number of dierent tissues, including breast tissue in ulnarmammary syndrome (Schinzel, 1987) . Taken together with the Tbx2 results and work presented here, a more comprehensive examination of Tbx2 and Tbx3 involvement in tumorigenesis is warranted.
Although the present observations point to a potential role for Tbx3 in tumorigenesis, our results may also shed some light on how mutations in Tbx3 lead to ulnar-mammary syndrome. In experiments using a mutant Tbx3 lacking its C-terminus, a mutant form of Tbx3 that is similar to those predicted to be produced by a number of Tbx3 mutations found in ulnar ± mammary syndrome Carlson et al., 2001) , we found that it failed to interfere with apoptosis ( Figures 2b and 3a,b ) and failed to block myogenic dierentiation (Figure 4) . Thus, perhaps UMS mutations lead to hypoplasia as a consequence of failure to adequately protect against apoptotic death of key cell populations at critical times during embryonic development. Alternatively or coincidentally, mutant Tbx3 proteins and/or Tbx3 de®ciency, may lead to the premature or unscheduled dierentiation of key target tissues. However, even though hypoplasia is evident in many tissues of UMS patients, UMS is a highly complex syndrome that does not appear to be a disease of cell proliferation per se, but more a disease of defective epithelial/ mesenchymal interactions (Bamshad et al., 1997; Smith, 1999) . Furthermore, regulation of p19ARF levels and p53 pathway activity and possibly pRb pathway activity (Figures 2a, 3c ) is likely to be but one aspect of Tbx3 function and it will be important to determine other Tbx3 target genes and biological activities. However, it is notable that mutations in the p53 family member p63, cause EEC syndrome (ectrodactyly, ectodermal dysplasia, and cleft lip/ palate) (Celli et al., 1999; van Bokhoven et al., 2001) , the related Hays ± Wells syndrome (McGrath et al., 2001) , and are found in a subset of individuals with non-syndromic split hand ± split foot malformation (SHFM) (Ianakiev et al., 2000; ) and limb-mammary syndrome (van . All of these diseases share some overlapping features with UMS, supporting the possibility that disrupted regulation of p53 and perhaps p63 in some aected tissues may indeed be an important underlying mechanism in this syndrome.
Materials and methods
Focus formation assays
Primary mouse embryo ®broblasts (MEFs) were isolated from embryonic day 13.5 mouse (C57Bl/6) embryos as previously described (Spector et al., 1998) and grown in DMEM supplemented with 10% FBS. Analogous to experiments pioneered by Land et al. (1983) , focus formation (transformation) assays were performed by transfecting MEFs at passage 1 or 2 with combinations of pBabe ± Myc (a kind gift from C Grandori) pEJ ± Hras and pCS2 ± Tbx3 plasmids (Carlson et al., 2001 ) using the calcium phosphate precipitation method (Chen and Okayama, 1987) . Transfected MEFs were fed every 2 days with growth medium and stained with methylene blue after 2 ± 3 weeks. Focus formation experiments were performed in duplicate and repeated with dierent batches of MEFs at least two times with essentially identical results. For soft agar assays, instead of staining cells used in focus formation assays, they were pooled and plated in duplicate at 5000 cells/plate in soft agar as previously described (Hurlin et al., 1987) . Soft agar assays were performed twice with reproducible results.
Retroviral infection and apoptosis assays
Retroviral infections of MEFs and HO-Myc (a kind gift of J Sedivy) cells were carried out for 24 h in DMEM/10% FBS using viral supernatants produced in transiently transfected Ecopak 293 cells (Clonetech). Infections were performed using pFB retrovirus (Stratagene), pFB ± Tbx3 ± Ha, or pFB ± Tbx3 ± 300 (Carlson et al., 2001 ), pBabe ± Myc and pBabe ± H-Ras (a kind gift from Scott Lowe). Virus titers were determined by infecting NIH3T3 cells with a pFB ± GFP (green¯uorescent protein) retrovirus and positive (green uorescent) cells counted. Typical infection eciencies were 50 ± 80%. For apoptosis assays, infected cells were plated at 50 000 cells per 30 mm dish 24 h after infection (or sequential infections) and serum levels were lowered 12 h later from 10% to 0.2% serum. Cells were photographed and collected daily, ®xed in 70% ethanol, stained with propidium iodide and sorted for DNA content by¯uorescence-activated cell sorting (FACS). Assays were performed at least three times.
Myogenic differentiation assays and Northern blotting
C2C12 cells (ATCC) were maintained in DMEM supplemented with 15% fetal calf serum (FCS) and grown in humidi®ed incubators at 378C and 10% CO 2 . To induce dierentiation, cells were grown to 90% con¯uence and growth medium switched to 2% horse serum (dierentiation medium) for 5 days. Cells were photographed daily. Northern blots were carried out using total RNA by standard methods and hybridized with radiolabelled probes for myoD, myogenin and myosin light chain (gifts from M Thayer) and GFAP.
Western blot analysis
For retrovirus-infected cells, cells were harvested 48 h after infection and lysed with NP-40 buer (150 mM NaCl, 20 mM Tris HCl pH 8, 1 mM EDTA, 1% NP-40, 10% glycerol, and 10 mg/ml Aprotinin, 1 mM PMSF, and 25 mg/ml leupeptin added fresh). Equal amounts of protein were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene di¯uoride membranes (Millipore Corp., Bedford, MA, USA). Membranes were incubated in TTBS (10 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20) containing 5% non-fat dry milk overnight at 48C. Membranes were probed using the following antibodies: p19ARF (Abcam), p53, p21, p16, c-Myc, tubulin (Santa Cruz Biotechnology), Mdm2 (A Levine, Princeton), pRb, and phospho-speci®c Rb (New England Biolabs), Ha epitope (Covance). Antibody incubations and washes were performed according to conditions provided by the supplier.
